1. Scrip
  2. >>Business

New appointment at Facet Biotech

 
• By Zoë Dann

Facet Biotech (US) has named Dr Ted Llana senior vice-president of commercial and corporate development. From September 2001 to November 2008, Dr Llana served in various positions at Biogen Idec, including most recently as vice-president of the oncology/rheumatology strategic business unit. Facet is a biotechnology company launched in December 2008 as a spin-off from PDL BioPharma.

Facet Biotech (US) has named Dr Ted Llana senior vice-president of commercial and corporate development. From September 2001 to November 2008, Dr Llana served in various positions at Biogen Idec, including most recently as vice-president of the oncology/rheumatology strategic business unit. Facet is a biotechnology company launched in December 2008 as a spin-off from PDL BioPharma.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.

Quotables: Pharma Leaders On The Month’s Hot Topics

 
• By Anabel Costa-Ferreira

The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.

In Brief: AbbVie’s Rinvoq Secures US Approval For Giant Cell Arteritis

 
• By Sushmita Panda

JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.